Becker's ASC

Simulation supports biologic therapy Entyvio as initial biologic ulcerative colitis treatment: 6 things to know

A study in Inflammatory Bowel Diseases used a novel simulation model to assess the optimal treatment positioning for patients with moderately to severely active ulcerative colitis and to predict ...
Healio

UC patients treated with Entyvio as first biologic therapy could see better outcomes

Please provide your email address to receive an email when new articles are posted on . Patients with moderate-to-severe ulcerative colitis treated with Entyvio as first-line biologic therapy could ...
Business Insider

Takeda's Entyvio and Janssen's Stelara Share of Inflammatory Bowel Disease Biologic-Naive Patients Continues to Increase as This Patient Group Expands Their Involvement in the ...

EXTON, Pa., July 30, 2020 /PRNewswire/ -- The 2020 audit included in Spherix's RealWorld Dynamix™: Biologic/Small Molecule New Starts in IBD (US) service focuses on a key bellwether of the ulcerative ...
Nasdaq

U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

− ENTYVIO Is the Only FDA-Approved Ulcerative Colitis Biologic That Offers the Choice of Intravenous or Subcutaneous Maintenance Therapy “With the FDA approval of subcutaneous ENTYVIO, patients and ...
Healio

Entyvio exhibits favorable real-world safety profile in biologic-naive IBD patients

SAN ANTONIO — Entyvio was associated with significantly fewer serious adverse events and serious infections compared with anti-TNF therapy in biologic-naive patients with inflammatory bowel disease, ...
Business Insider

The Need for Greater Efficacy Drives Increased Switching from Branded TNF Inhibitors to Takeda's Entyvio, Janssen's Stelara, and Pfizer's Xeljanz in US Inflammatory Bowel ...

EXTON, Pa., Sept. 24, 2020 /PRNewswire/ -- The 2020 audit included in Spherix's RealWorld Dynamix™: Biologic/Small Molecule Switching in IBD (US) service focuses on a critical facet of overall ...
Nasdaq

European Commission Approves Subcutaneous Formulation of Entyvio® (Vedolizumab) for use as Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis ...

− Approval makes Entyvio the only maintenance therapy approved across Europe with both intravenous and subcutaneous formulation options for adult patients with ulcerative colitis or Crohn’s disease − ...
PharmaTimes

NICE U-turn as Entyvio is backed for Crohn’s

Patients with Crohn’s disease are now likely to get National Health Service access to Takeda’s biologic Entyvio in England and Wales following a u-turn by the National Institute for Health and Care ...
AOL

Does Medicare Cover Entyvio

Entyvio is a brand-name prescription medication known as a biologic. Its active ingredient is called vedolizumab. Generic versions of biologic medications are called biosimilars. But only the ...
FiercePharma

FDA Approves Takeda's Entyvio™ (vedolizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

FDA Approves Takeda's Entyvio™ (vedolizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Deerfield, Ill., May 20, 2014, and Osaka, Japan, May ...
AOL

Medicare coverage for Entyvio: What to know

Entyvio is a brand-name prescription biologic drug. It contains the active ingredient vedolizumab. Biosimilars are generic versions of biologic medications, but only the brand-name version of this ...